RxDoctor Payments DataLook up a doctor →

David Spigel, MD

Medical Oncology · Nashville, TNNPI 1427074210

Payments from drug & device makers

$29,707,537in general payments, 2019–2025

Across 3,561 payments — averaging $8342.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • E.r. Squibb & Sons, L.L.C.$5.7M
  • Merck$5.2M
  • Genentech, Inc.$2.9M
  • AstraZeneca$2.9M
  • Astrazeneca UK Limited$2.8M
  • GSK$1M
  • plus $9.1M from 54 others
$40,511in research payments, 2019–2025

Across 22 payments — averaging $1841.43 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • F. Hoffmann-la Roche AG$22K
  • Bristol Myers Squibb$18K
  • GSK$285

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
E.r. Squibb & Sons, L.L.C.178$5,731,276
Merck227$5,242,123
Genentech, Inc.575$2,915,824
AstraZeneca128$2,875,428
Astrazeneca UK Limited59$2,838,026
GSK330$1,028,432
Beigene, Ltd.228$894,954
Boehringer Ingelheim International GmbH54$625,921
G1 Therapeutics, Inc.38$578,664
Eli Lilly28$554,418
Amgen20$511,367
Ipsen Bioscience Inc.135$483,408
Janssen Research & Development, LLC176$471,051
Tesaro, Inc.32$453,892
Blueprint Medicines Corporation91$414,842
Jazz Pharmaceuticals Inc.47$406,291
Novartis24$354,548
Taiho Oncology, Inc.85$310,664
Bristol Myers Squibb9$280,062
Servier Bioinnovation52$238,495
Biontech SE82$235,739
Boehringer Ingelheim23$227,347
Daiichi Sankyo Inc.80$217,566
Astellas Pharma Global Development79$205,530
EMD Serono, Inc.55$170,386
Modernatx, Inc.62$167,803
Bayer40$147,456
Seagen Inc.47$143,465
Novocure Inc.38$118,012
Eisai Inc.86$114,725
Incyte Corporation78$103,305
Ipsen Biopharmaceuticals, Inc1$91,500
Chugai Pharmaceutical Co., Ltd.45$76,969
Ascendis Pharma Endocrinology Inc18$67,747
Takeda Pharmaceuticals U.S.A., Inc.37$64,893
Novocure GmbH28$64,256
AbbVie40$49,693
Acerta Pharma LLC1$28,625
Macrogenics, Inc.26$27,696
Sanofi US Services Inc.9$26,178
Karyopharm Therapeutics Inc.6$23,317
PTC Therapeutics, Inc.16$18,752
Servier Pharmaceuticals LLC14$18,341
F. Hoffmann-la Roche AG19$18,182
Agios Pharmaceuticals, Inc.3$17,224
Boehringer Ingelheim Pharma GmbH & Co.kg9$12,423
Sanofi Pasteur Inc.2$7,985
Pfizer8$5,596
Nuvation Bio Inc.2$5,000
Genentech USA, Inc.9$4,838
Sanofi5$4,797
Beigene USA, Inc.2$2,524
Novartis Pharma AG1$2,320
Regeneron1$1,965
Roche Molecular Systems, Inc.4$1,744
Astrazeneca AB8$1,432
Exelixis Inc.4$706
Viiv Healthcare Company1$334
Regeneron Healthcare Solutions, Inc.10$257
Gilead5$229

How this compares

$29,707,537 in reported general payments places this provider in the 95th percentile of 101 medical oncology providers in Tennessee.

See all medical oncology providers in Tennessee →

Medicare billing

Part B allowed, 2024
$1,388,861
Medicare patients
174
Services billed
39,878

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other medical oncology in Nashville

See the full list for Tennessee →

Where these figures come from

Is this you, or does something look wrong? →